

IL-17A Protein, Human, Recombinant V2

General Information

Synonyms:	interleukin 17A;CTLA8;IL-17A;IL17;IL-17;CTLA-8
Protein Construction:	Gly24-Ala155
Species:	Human
Expression Host:	E. coli
Accession:	Q16552
Molecular Weight:	15.26 kDa (Predicted); 16 kDa (Reducing conditions)

QC Testing

Biological Activity:	Immobilized Human AXL-His at 10µg/ml (100 µl/well) can bind Human GAS6-His*.*: Biotinylated by NHS-biotin prior to testing The ED50 of Recombinant Human GAS6-His* is 0.04466 ug/ml. (Regularly tested)
Purity:	> 95% as determined by SDS-PAGE
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a 0.2 µm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in sterile deionized water. The product concentration should not be less than 100 µg/mL. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with

specific inhibitors provides a protective inhibition of cartilage and bone degradation.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481